Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receiver Operating Characteristic Plot01:15

Receiver Operating Characteristic Plot

78
A ROC (Receiver Operating Characteristic) plot is a graphical tool used to assess the performance of a binary classification model by illustrating the trade-off between sensitivity (true positive rate) and specificity (false positive rate). By plotting sensitivity against 1 - specificity across various threshold settings, the ROC curve shows how well the model distinguishes between classes, with a curve closer to the top-left corner indicating a more accurate model. The area under the ROC curve...
78
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

120
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
120
Hazard Ratio01:12

Hazard Ratio

90
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
90
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

504
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
504
Relative Risk01:12

Relative Risk

117
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
117
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

132
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
132

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Putting clinical studies into better perspective by defining accuracy when effect size is small.

Clinica chimica acta; international journal of clinical chemistry·2025
Same author

Accuracy of the Number Needed to Treat Compared With Diagnostic Testing: Brief Critical Review.

Archives of pathology & laboratory medicine·2022
Same author

Is Measurement of Systemic IgG Antibodies the Wrong Way to Assess COVID-19 Vaccine Effectiveness for Breakthrough Infections?

The journal of applied laboratory medicine·2022
Same author

The Predicament of Large Numbers of Observations and How We Got There: Critical Review.

The journal of applied laboratory medicine·2020
Same author

SARS-CoV-2 Serology-Need for Quantitative Testing and Interpretive Reporting.

The journal of applied laboratory medicine·2020
Same author

Non-High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History.

Laboratory medicine·2019

Related Experiment Video

Updated: Jun 5, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.2K

Non-HDL Cholesterol May Be Preferred over Apolipoprotein B-100 for Risk Assessment when Evaluated by Receiver

Stanley S Levinson1

  • 1Department of Medicine, Section of Endocrinology, Metabolism and Diabetes, University of Louisville, Louisville, KY, United States.

The Journal of Applied Laboratory Medicine
|December 13, 2024
PubMed
Summary

Apolipoprotein B (apo B)-100 is a strong coronary risk marker, but non-HDL cholesterol (non-HDLC) offers similar clinical efficacy at a lower cost. Both are superior to LDL cholesterol for risk assessment.

More Related Videos

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

8.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Related Experiment Videos

Last Updated: Jun 5, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.2K
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

8.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Area of Science:

  • Cardiovascular Disease Biomarkers
  • Lipid Metabolism and Atherosclerosis

Background:

  • Apolipoprotein B (apo B)-100 is often considered a superior marker for coronary risk compared to non-high-density lipoprotein (HDL) cholesterol (non-HDLC).
  • Multivariate analyses with highly correlated variables, such as lipid markers, present interpretation challenges and hinder discrimination of effects.
  • Assessing the clinical utility and cost-effectiveness of different lipid markers is crucial for accurate cardiovascular risk stratification.

Purpose of the Study:

  • To compare the diagnostic sensitivity and specificity of apolipoprotein B (apo B)-100 and non-HDL cholesterol (non-HDLC) for coronary risk assessment.
  • To evaluate the clinical value of apo B in relation to its additional expense compared to non-HDLC.
  • To analyze lipid markers using receiver operator characteristic (ROC) curves for robust discrimination.

Main Methods:

  • A brief review and examination of diagnostic performance using receiver operator characteristic (ROC) curves.
  • Measurement of apo B and various cholesterol fractions (non-HDLC, LDL-C, total C) in 382 patients with angiographically defined coronary artery disease.
  • Logistic regression and ROC analysis were employed to compare marker performance, with and without adjustment for nonlipid risk factors.

Main Results:

  • Both apo B and non-HDLC demonstrated stronger coronary risk marker performance than LDL cholesterol (LDL-C) and total cholesterol (total C) via ROC analysis.
  • Despite strong collinearity issues where non-HDLC appeared weaker than LDL-C in multivariate logistic regression, ROC analysis showed apo B had 6.1% greater sensitivity than non-HDLC when analyzed alone.
  • After adjusting for nonlipid risk factors, apo B and non-HDLC exhibited similar C statistics (0.74 and 0.73, respectively) with minimal differences in diagnostic specificity.

Conclusions:

  • Non-HDL cholesterol (non-HDLC) presents a cost-effective alternative to apolipoprotein B (apo B)-100 for cardiovascular risk assessment.
  • When incorporated into a 10-year screening algorithm alongside nonlipid risk factors, non-HDLC offers comparable clinical efficacy to apo B.
  • The findings support the use of non-HDLC as a clinically effective and more economical marker for coronary risk stratification.